PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Respiratory

Drug development

Coverage of the development arc of new therapies - trial design, endpoint selection, accelerated vs traditional approval pathways, and what the readouts tell us about where the field is heading. 5 pieces on drug development in Respiratory, newest first within each collection.

← All topics
FilterAll (69)Oncology (10)Rare Disease (9)Immunology (7)Neurology (21)Cardiometabolic (8)Respiratory (5)Women's Health (1)Mental Health (3)Ophthalmology (5)

Signals

4
SignalNEWMay 7, 2026

Severe COPD biologic therapy class emerges past the inhaler era

Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.

TreatmentBiomarkersPipelineDrug development
SignalNEWMay 5, 2026

Obstructive sleep apnea pharmacotherapy emerges past CPAP-and-MAD

Tirzepatide OSA approval, follow-on GLP-1 OSA programs, and upper airway pharmacological programs are reshaping obstructive sleep apnea management.

TreatmentPipelineDeliveryDrug development
SignalNEWMay 4, 2026

Refractory chronic cough acquires a first targeted mechanism class

P2X3 antagonist class entry plus follow-on novel mechanism programs are establishing chronic cough as a real prescribing category.

TreatmentPipelineDiagnosisDrug development
SignalNEWMay 4, 2026

Sarcoidosis acquires mechanism-targeted therapy after a long quiet period

Efzofitimod late-stage data and other emerging mechanism-targeted programs are reshaping pulmonary sarcoidosis after years of corticosteroid-only first-line.

TreatmentPipelineDrug development

Explained

1
ExplainedApr 26, 2026peer-reviewed · industry-filing

How chronic cough has emerged as a discrete indication with its own pipeline

Chronic cough was historically managed within the broader respiratory and ENT framework as a symptom rather than as an indication. The emergence of P2X3 receptor antagonists and adjacent novel mechanisms has established chronic cough as a discrete therapeutic indication with a distinct pipeline, regulatory pathway and commercial logic.

PipelineTreatmentDrug development